24/7 Market News Snapshot 29 September, 2025 – Eupraxia Pharmaceuticals Inc. Common Stock (NASDAQ:EPRX)

September 29, 2025

DENVER, Colo., 29 September, 2025 (www.247marketnews.com) – (NASDAQ:EPRX) are discussed in this article.
Eupraxia Pharmaceuticals Inc. has demonstrated significant momentum in the market, with shares opening at $5.78 and experiencing a remarkable surge of 18.45%, reaching a trading price of $6.80. This upward trend is underpinned by considerable trading volume, totaling approximately 1.12 million shares, reflecting intensified investor interest. Analysts note that sustained trading above the $6.75 resistance level may open the door to further gains, potentially targeting the next resistance around $7.50. Conversely, support levels at approximately $6.00 should be monitored to manage risk effectively. Overall, the burgeoning bullish sentiment surrounding Eupraxia Pharmaceuticals signifies optimistic expectations about the company’s future.

In parallel to its market performance, Eupraxia Pharmaceuticals has made notable strides in its clinical development of EP-104GI, a groundbreaking therapy targeting Eosinophilic Esophagitis (EoE). Recent data from the RESOLVE trial’s Cohort 9 has showcased promising results, particularly for patients receiving the highest 8 mg dosage, who exhibited remarkable improvements in both tissue health and eosinophil reduction. Dr. James A. Helliwell, CEO of Eupraxia, expressed enthusiasm for the trial outcomes, reinforcing the company’s belief that the 8 mg dosage is optimal and should be further evaluated in the ongoing Phase 2b study.

In response to these positive results, Eupraxia plans to expand the Phase 2b segment of the RESOLVE study to include at least 120 patients, enhancing the trial’s statistical efficacy and increasing the possibility of attaining breakthrough designation from regulatory agencies. Furthermore, the company is poised to initiate additional trials for new gastrointestinal indications in early 2026, capitalizing on its proprietary Diffusphere™ technology that offers controlled and targeted drug delivery. A webinar is scheduled for October 1st at 8 AM PDT, during which the company will provide further details regarding the recent clinical advancements and their implications for the treatment landscape.

Related news for (EPRX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.